Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$4.70

-0.105 (-2.19%)

06:04
12/17/19
12/17
06:04
12/17/19
06:04

Kala Pharmaceuticals downgraded to Neutral from Buy at BofA/Merrill

BofA/Merrill downgraded Kala Pharmaceuticals to Neutral from Buy.

KALA Kala Pharmaceuticals
$4.70

-0.105 (-2.19%)

04/25/19
04/25/19
INITIATION
Target $11

Outperform
Oppenheimer initiates Kala with Outperform, sees attractive growth story
As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Kala Pharmaceuticals with an Outperform rating and $11 price target. With strong initial uptake of Inveltys, and KPI-121 regulatory catalyst in Q3, the analyst believes Kala Pharmaceuticals is well positioned for top line growth. His channel checks with ocular surgeons support Inveltys prescription growth over the next twelve months. Separately, he believes KPI-121 may address a significant unmet need in the nascent dry eye disease market.
06/25/19
STFL
06/25/19
NO CHANGE
STFL
Evolus can benefit from 'distraction' at Allergan, says Stifel
After AbbVie (ABBV) announced its intention to acquire Allergan (AGN), Stifel analyst Annabel Samimy said the former clearly sees the latter's Medical Aesthetics business "as a premier, durable, cash-pay franchise and a leader in its field." However, she noted that AbbVie committed to keeping it as a separate business under the Allergan name, which leads Samimy to believe that a spinoff of aesthetics remains a possibility. She also said she would expect "meaningful distraction" at Allergan, "as typical in the midst of an acquisition," which can benefit competitor Evolus (EOLS) as it launches Jeuveau. Samimy, who concluded that she sees today's news potentially bringing interest back to the "washed out" biopharma group, names Revance (RVNC), Aerie Pharmaceuticals (AERI), TherapeuticsMD (TXMD) and Kala Pharmaceuticals (KALA) as being among the potentially attractive targets.
10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.
11/11/19
HCWC
11/11/19
NO CHANGE
Target $10
HCWC
Buy
Kala Pharmaceuticals price target lowered to $10 from $12 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered his price target for Kala Pharmaceuticals to $10 from $12 and reiterates a Buy rating on the shares following the company's Q3 results. The analyst reduced his projected sales of Inveltys going forward.

TODAY'S FREE FLY STORIES

AAPL

Apple

$318.66

3.33 (1.06%)

15:41
01/20/20
01/20
15:41
01/20/20
15:41
Periodicals
Apple CEO says global corporate tax system must be overhauled, Reuters reports »

Baking changes to global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:27
01/20/20
01/20
15:27
01/20/20
15:27
Periodicals
Alphabet calls for 'proportionate approach' to AI regulation, Reuters reports »

Sundar Pichai, the CEO of…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:24
01/20/20
01/20
15:24
01/20/20
15:24
Periodicals
Alphabet CEO backs temporary ban on facial-recognition, Reuters reports »

The EU's proposal…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

MSFT

Microsoft

$167.06

0.82 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

  • 25

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, AER

AerCap

$62.35

-0.18 (-0.29%)

15:10
01/20/20
01/20
15:10
01/20/20
15:10
Periodicals
AerCap CEO warns against panic discounts for Boeing 737 MAX, Reuters says »

Owners of Boeing's…

BA

Boeing

$324.11

-7.89 (-2.38%)

AER

AerCap

$62.35

-0.18 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 13

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

15:05
01/20/20
01/20
15:05
01/20/20
15:05
Periodicals
Aviation executive says Boeing should ditch 'MAX,' NY Post reports »

Steven Udvar-Hazy is the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BA

Boeing

$324.11

-7.89 (-2.38%)

14:08
01/20/20
01/20
14:08
01/20/20
14:08
Periodicals
Boeing close to securing $10B loan, Bloomberg reports »

Boeing is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CAE

CAE

$29.65

-0.14 (-0.47%)

14:05
01/20/20
01/20
14:05
01/20/20
14:05
Hot Stocks
CAE appoints Todd Probert as Group President, Defense & Security »

CAE announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ACC

American Campus

$46.31

-0.085 (-0.18%)

14:03
01/20/20
01/20
14:03
01/20/20
14:03
Recommendations
American Campus analyst commentary  »

American Campus announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

UPS

UPS

$118.61

0.005 (0.00%)

14:02
01/20/20
01/20
14:02
01/20/20
14:02
Hot Stocks
UPS launches e-commerce plug-ins as part of UPS Digital Access Program »

UPS announced that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

WINS

Wins Finance

$12.50

-1.2 (-8.76%)

13:58
01/20/20
01/20
13:58
01/20/20
13:58
Hot Stocks
Wins Finance announces submission of compliance plan to Nasdaq »

Wins Finance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$167.06

0.82 (0.49%)

13:55
01/20/20
01/20
13:55
01/20/20
13:55
Recommendations
Microsoft price target raised to $175 from $160 at Stifel »

Stifel analyst Brad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 25

    Feb

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

13:52
01/20/20
01/20
13:52
01/20/20
13:52
Periodicals
Softbank says WeWork still good business at core, Bloomberg reports »

SoftBank (SFTBY;SFTBF)…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EGLE

Eagle Bulk Shipping

$4.25

-0.03 (-0.70%)

13:40
01/20/20
01/20
13:40
01/20/20
13:40
Conference/Events
Eagle Bulk Shipping to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:39
01/20/20
01/20
13:39
01/20/20
13:39
Downgrade
Siam Commercial Bank rating change at JPMorgan »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:38
01/20/20
01/20
13:38
01/20/20
13:38
Downgrade
Siam Commercial Bank rating change at Credit Suisse »

Siam Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change at Macquarie »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change at Citi »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

13:35
01/20/20
01/20
13:35
01/20/20
13:35
Downgrade
ConvaTec rating change at JPMorgan »

ConvaTec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
01/20/20
01/20
13:35
01/20/20
13:35
General news
FX Summary: Activity was moribund »

FX Summary: Activity was…

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

13:31
01/20/20
01/20
13:31
01/20/20
13:31
Recommendations
Kansas City Southern analyst commentary at BMO Capital »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$182.16

-0.53 (-0.29%)

13:06
01/20/20
01/20
13:06
01/20/20
13:06
Recommendations
BMO keeps 'top pick' status on Salesforce, boosts price target to $210 »

BMO Capital analyst Keith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

SNYYF

Sany Heavy

$0.00

(0.00%)

12:56
01/20/20
01/20
12:56
01/20/20
12:56
Upgrade
Sany Heavy rating change at Goldman Sachs »

Sany Heavy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATDRY

Auto Trader Group

$0.00

(0.00%)

12:52
01/20/20
01/20
12:52
01/20/20
12:52
Upgrade
Auto Trader Group rating change at Goldman Sachs »

Auto Trader Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIOSF

Atresmedia

$0.00

(0.00%)

12:50
01/20/20
01/20
12:50
01/20/20
12:50
Downgrade
Atresmedia rating change at Goldman Sachs »

Atresmedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGDDF

Lagardere

$0.00

(0.00%)

12:48
01/20/20
01/20
12:48
01/20/20
12:48
Downgrade
Lagardere rating change at Goldman Sachs »

Lagardere downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.